BlossomHill Therapeutics

BlossomHill Therapeutics is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on designing and developing next-generation small-molecule cancer medicines. Founded in 2020 by J. Jean Cui, Ph.D., the company approaches drug design from first principles — combining human intelligence, creative thinking, and proven drug design expertise to develop what it calls 'small-molecule masterpieces' with the potential to set new standards in oncology. Its pipeline targets key oncogenic drivers including EGFR mutations in non-small cell lung cancer (NSCLC) and CLK-mediated pathways in hematologic malignancies such as relapsed/refractory AML and HR-MDS, as well as pan-KRAS programs. BlossomHill has raised over $257 million from leading life sciences investors including Cormorant Asset Management, with programs advancing through Phase 1/1b clinical trials.